• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

代偿期肝硬化:自然史及预后因素

Compensated cirrhosis: natural history and prognostic factors.

作者信息

Ginés P, Quintero E, Arroyo V, Terés J, Bruguera M, Rimola A, Caballería J, Rodés J, Rozman C

出版信息

Hepatology. 1987 Jan-Feb;7(1):122-8. doi: 10.1002/hep.1840070124.

DOI:10.1002/hep.1840070124
PMID:3804191
Abstract

To investigate the natural history of compensated cirrhosis, 293 consecutive patients without previous major complications (ascites, jaundice, encephalopathy or gastrointestinal hemorrhage) were studied in terms of morbidity (probability of developing decompensated cirrhosis during follow-up) and survival. Patients were diagnosed by liver histology between 1968 and 1980. Median follow-up was 63 months. Decompensation of cirrhosis was considered when a patient first developed one of the major complications of the disease. Ten years after diagnosis, the probability of developing decompensated cirrhosis and the survival probability rate were 58 and 47%, respectively. A multivariate survival analysis (Cox's regression model) using clinical, biochemical and histological data obtained at diagnosis disclosed seven factors that predicted prognosis: serum bilirubin; serum gamma-globulin concentration; hepatic stigmata; prothrombin time; sex; age, and alkaline phosphatase. According to the contribution of each one of these factors to the final model, a prognostic index was constructed that allows calculation of the estimated survival probability. The predicting value of this index was validated by a split sample testing technique.

摘要

为了研究代偿期肝硬化的自然病史,我们对293例无既往重大并发症(腹水、黄疸、肝性脑病或胃肠道出血)的连续患者进行了发病率(随访期间发展为失代偿期肝硬化的概率)和生存率方面的研究。患者于1968年至1980年间经肝脏组织学诊断。中位随访时间为63个月。当患者首次出现该疾病的一项重大并发症时,即视为肝硬化失代偿。诊断后十年,发展为失代偿期肝硬化的概率和生存率分别为58%和47%。使用诊断时获得的临床、生化和组织学数据进行的多变量生存分析(Cox回归模型)揭示了七个预测预后的因素:血清胆红素;血清γ-球蛋白浓度;肝脏体征;凝血酶原时间;性别;年龄和碱性磷酸酶。根据这些因素中每一个对最终模型的贡献,构建了一个预后指数,用于计算估计的生存概率。该指数的预测价值通过拆分样本测试技术进行了验证。

相似文献

1
Compensated cirrhosis: natural history and prognostic factors.代偿期肝硬化:自然史及预后因素
Hepatology. 1987 Jan-Feb;7(1):122-8. doi: 10.1002/hep.1840070124.
2
An analysis of prognostic factors in cirrhosis.肝硬化预后因素分析
Chin Med J (Engl). 1989 Apr;102(4):266-72.
3
Survival and prognostic indicators in compensated and decompensated cirrhosis.代偿期和失代偿期肝硬化的生存及预后指标
Dig Dis Sci. 1986 May;31(5):468-75. doi: 10.1007/BF01320309.
4
Predictive role of serum procollagen III peptide and Knodell's index in survival prognosis of patients with hepatitis B virus liver cirrhosis.血清Ⅲ型前胶原肽和Knodell指数对乙型肝炎病毒肝硬化患者生存预后的预测作用
Wien Klin Wochenschr. 2003 May 15;115(9):302-8. doi: 10.1007/BF03040336.
5
Prognostic significance of hepatic encephalopathy in patients with cirrhosis.肝硬化患者肝性脑病的预后意义
J Hepatol. 1999 May;30(5):890-5. doi: 10.1016/s0168-8278(99)80144-5.
6
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.肝静脉压力梯度可预测代偿期肝硬化患者的临床失代偿情况。
Gastroenterology. 2007 Aug;133(2):481-8. doi: 10.1053/j.gastro.2007.05.024. Epub 2007 May 21.
7
Prognostic indicators of survival in patients with cirrhosis and esophageal varices, without previous bleeding.肝硬化合并食管静脉曲张且既往无出血史患者的生存预后指标
Am J Gastroenterol. 1989 Jul;84(7):717-22.
8
Prognostic factors of survival in complicated viral and alcoholic cirrhosis without hepatocellular carcinoma. A retrospective study.无肝细胞癌的复杂病毒性和酒精性肝硬化患者生存的预后因素。一项回顾性研究。
Minerva Gastroenterol Dietol. 2007 Dec;53(4):311-9.
9
Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP).366例B型代偿期肝硬化患者的生存及预后因素:一项多中心研究。欧洲病毒性肝炎联合行动组织(EUROHEP)的研究人员。
J Hepatol. 1994 Oct;21(4):656-66. doi: 10.1016/s0168-8278(94)80115-0.
10
Indocyanine green intrinsic hepatic clearance as a prognostic index of survival in patients with cirrhosis.吲哚菁绿肝脏固有清除率作为肝硬化患者生存的预后指标。
J Hepatol. 1989 Jul;9(1):16-22. doi: 10.1016/0168-8278(89)90070-6.

引用本文的文献

1
Detecting decompensation in cirrhotic patients with varying ascitic volumes using magnetic resonance elastography.利用磁共振弹性成像技术检测不同腹水量的肝硬化患者的失代偿情况。
Abdom Radiol (NY). 2025 Sep 13. doi: 10.1007/s00261-025-05197-z.
2
Comparison of Zinc Levels in Liver Cirrhosis and Evaluating the Severity Using Child-Pugh Score.肝硬化患者锌水平的比较及应用Child-Pugh评分评估严重程度
Cureus. 2025 Jul 4;17(7):e87277. doi: 10.7759/cureus.87277. eCollection 2025 Jul.
3
Generative AI in hepatology: Transforming multimodal patient-generated data into actionable insights.
肝病学中的生成式人工智能:将多模式患者生成的数据转化为可操作的见解。
Hepatol Commun. 2025 Jul 14;9(8). doi: 10.1097/HC9.0000000000000683. eCollection 2025 Aug 1.
4
NASH-CHECK patient-reported outcome instrument: evaluation of content and face validity for patients with metabolic dysfunction-associated steatohepatitis and compensated cirrhosis.NASH-CHECK患者报告结局量表:对代谢功能障碍相关脂肪性肝炎和代偿期肝硬化患者的内容效度和表面效度评估
J Patient Rep Outcomes. 2025 Jul 1;9(1):76. doi: 10.1186/s41687-025-00881-6.
5
Palliative long-term abdominal drains vs. large volume paracentesis for refractory ascites secondary to cirrhosis: protocol for a definitive randomised controlled trial (REDUCe2 study).姑息性长期腹腔引流与大量腹腔穿刺术治疗肝硬化继发性难治性腹水的比较:一项确定性随机对照试验方案(REDUCe2研究)
Trials. 2025 Jun 4;26(1):193. doi: 10.1186/s13063-025-08873-z.
6
Ascites complications risk factors of decompensated cirrhosis patients: logistic regression and prediction model.失代偿期肝硬化患者腹水并发症的危险因素:逻辑回归与预测模型
BMC Gastroenterol. 2025 May 22;25(1):397. doi: 10.1186/s12876-025-04002-x.
7
PERFORMANCE OF SIX PREDICTIVE MODELS OF DEATH OF PATIENTS HOSPITALIZED FOR DECOMPENSATED CIRRHOSIS: A MULTICENTER STUDY.失代偿期肝硬化住院患者六种死亡预测模型的性能:一项多中心研究
Arq Gastroenterol. 2025 Apr 4;62:e24065. doi: 10.1590/S0004-2803.24612024-065. eCollection 2025.
8
From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension.从病理生理学到临床实践:门静脉高压症不断发展的药物治疗、临床并发症及药物遗传学考量
Metabolites. 2025 Jan 23;15(2):72. doi: 10.3390/metabo15020072.
9
CROATIAN GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF PORTAL HYPERTENSION.克罗地亚门静脉高压诊断与治疗指南。
Acta Clin Croat. 2024 Apr;63(1):214-243. doi: 10.20471/acc.2024.63.01.26.
10
Hyponatremia unleashes neutrophil extracellular traps elevating life-threatening pulmonary embolism risk.低钠血症引发中性粒细胞胞外诱捕网,增加危及生命的肺栓塞风险。
Proc Natl Acad Sci U S A. 2024 Nov 5;121(45):e2404947121. doi: 10.1073/pnas.2404947121. Epub 2024 Oct 30.